When patient data is generated outside the system, healthcare loses clinical control, medical time, and strategic advantage—and no company in the sector remains on the sidelines.
By Ehab Soltan
HoyLunes — The European healthcare system is beginning to fail in silence. Not due to a lack of resources, nor an absence of innovation, but because of a structural incapacity to process the new type of clinical data: the one that is no longer born within the system.
The thesis is clear and operative: the European healthcare system is entering a silent crisis because relevant clinical data is no longer generated exclusively within its structures, and there is no real capacity to integrate it, validate it, nor convert it into actionable medical decisions.
We are witnessing a structural shift in the origin of clinical data. Historically, medical data was born and died within the hospital; it was the property and responsibility of the physician. Today, the data is born outside. It is born in the wearable that monitors heart rate variability (HRV) during sleep, in private genetic or microbiome tests that the patient pays for out of pocket, in chronic disease management apps, and in longevity optimization platforms.
The system receives a tide of information that it simply does not know how to process. There is no technical integration, there are no clinical validation protocols for this “exogenous” data, and, crucially, there is no clear legal responsibility regarding what happens if a doctor ignores an adverse data point generated by a consumer device.
This is not an abstract problem. It is an operational failure that already translates into tangible costs: wasted clinical time, delayed decisions, and a progressive loss of control over the actual patient journey.
The Clash of Two Incompatible Speeds
This friction is not a transitory technical problem; it is a profound structural tension between two opposing operational philosophies that coexist in the same space and time.
| The “Activated” Patient | The Structured Healthcare System |
| Fast: Demands near-immediate responses and interventions based on their data. | Slow: Moves at the speed of consolidated clinical evidence and annual budgets. |
| Digital: Native in the capture, sharing, and analysis of fluid information. | Bureaucratic: Based on forms, information silos, and legacy workflows. |
| Predictive: Seeks to anticipate deterioration, optimize performance, and manage risks. | Reactive: Designed (and funded) primarily to diagnose and treat manifest disease. |
| Personalized: Demands an n=1; micro-interventions based on their unique biology. | Standardized: Operates through clinical practice guidelines and protocols for average populations. |
This table is not just a comparison; it is the map of the inefficiency that is operationally bleeding institutions. The result is not just inefficiency; it is a net loss of clinical authority to external actors who do know how to operate with distributed data.
When Friction Becomes Cost: Real Consequences
If you head a medical technology provider company, a pharmaceutical, or a clinical network, it is very likely that this friction is already affecting your bottom line or your operational capacity.
At the clinical level, we are seeing delayed decisions and valuable data systematically ignored due to the inability to separate it from the noise. A recent study published in NPJ Digital Medicine pointed out that, although wearables can detect arrhythmias, the lack of integration into real medical workflows drastically limits their clinical utility, often generating more anxiety than tangible results.
At the operational level, this translates into a massive loss of medical time. Consultations become saturated with patients who bring 50-page PDF reports generated by private apps, demanding that the doctor interpret them in a 15-minute visit. The result is professional burnout and systemic inefficiency.
Strategically, the risk is paralysis by analysis and loss of control. By not being able to process this information, the traditional healthcare system cedes clinical authority and the “patient journey” to new external actors (healthtech, big tech) who do possess the infrastructure to manage distributed data, fragmenting care even further.
The Design Error: Managing Diseases in the Era of Distributed Information
The system’s error is not a lack of will or physician technophobia. It is an error of strategic design: The European healthcare system remains designed to manage acute disease within physical walls… not to process distributed and continuous biological information.
We continue trying to apply a centralized and industrial logic to a phenomenon that is, by nature, decentralized and digital.
Here is where the true strategic opportunity emerges, a new category that is not generic “telemedicine” or “digital health.” We are facing the urgent need for a Clinical Data Translation Infrastructure. This does not constitute an incremental improvement; it is a new critical and necessary layer for the sustainability of the healthcare system.
This new infrastructure layer must not limit itself to connecting pipes (technical interoperability), but rather must execute four vital functions before the data reaches the doctor:
Validate: Evaluate the clinical and technical reliability of the data source.
Prioritize: Filter the tide of information and identify only what is clinically relevant and urgent.
Integrate: Insert the validated and prioritized data directly into the doctor’s workflow (EHR), not as an attachment, but as a native part of the medical history.
Act: Define what clinical, administrative, or triage decision that validated data automatically generates.
The European Insight: Interoperability Before Innovation
This challenge has critical nuances in the European context. With strict regulations like GDPR and the future European Health Data Space (EHDS), and heavily structured health systems but with uneven digitalization levels, the approach must be different from the US one. This means that Europe not only needs to innovate; it needs to urgently decide who controls the infrastructure that will make that innovation operative.
In Germany, the Digital Healthcare Act (DVG) has opened the door to DiGA (prescribable health apps), but real integration with hospital systems remains a major challenge. In the Netherlands, leaders in digital adoption, the fragmentation of EHR providers slows down the vision of fluid data.
This leads us to a powerful insight: Europe does not have a medical innovation problem. It has an execution and operational interoperability problem. Continuing to fund pilots for new apps without solving the clinical translation infrastructure is, quite simply, throwing money away.
If we do not lead this transition from within the system, the future risk is clear: critical medical decisions and the most effective prevention strategies will be made outside the formal healthcare system. We will lose clinical authority and care will fragment into private-pay niches, widening the gap of biological inequality that we have already analyzed in these pages.
For tech companies, clinical networks, and digital health platforms, this is not just an operational crisis. It is an unprecedented structural opportunity: build the infrastructure layer that the system does not yet have and that everyone will end up needing.
The debate is not technological. It is about the design of clinical power in the next decade. The final question is uncomfortable and purely strategic:
Who is going to design the system that connects what the patient already knows with what medicine can do?
Because whoever designs that system will not just organize data; they will define who decides, when action is taken, and who controls the future of health.
HealthTech #Interoperability #DataStrategy #SistemasSanitarios #InnovaciónMédica #EHDS #HoyLunes #EhabSoltan
